FDA Grants Breakthrough Therapy Designation To Pradaxa® (Dabigatran Etexilate) Specific Investigational Antidote

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab* (a humanized antibody fragment), currently being studied as a specific antidote for the oral anticoagulant Pradaxa® (dabigatran etexilate).3

Help employers find you! Check out all the jobs and post your resume.